WO1993018055B1 - Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160 - Google Patents

Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160

Info

Publication number
WO1993018055B1
WO1993018055B1 PCT/US1993/001925 US9301925W WO9318055B1 WO 1993018055 B1 WO1993018055 B1 WO 1993018055B1 US 9301925 W US9301925 W US 9301925W WO 9318055 B1 WO9318055 B1 WO 9318055B1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
acid sequence
amino acid
respone
peptides
Prior art date
Application number
PCT/US1993/001925
Other languages
French (fr)
Other versions
WO1993018055A3 (en
WO1993018055A2 (en
Filing date
Publication date
Priority claimed from US07/847,311 external-priority patent/US5976541A/en
Application filed filed Critical
Priority to CA002131153A priority Critical patent/CA2131153C/en
Priority to EP93907180A priority patent/EP0630385A1/en
Priority to AU37878/93A priority patent/AU668927B2/en
Publication of WO1993018055A2 publication Critical patent/WO1993018055A2/en
Publication of WO1993018055A3 publication Critical patent/WO1993018055A3/en
Publication of WO1993018055B1 publication Critical patent/WO1993018055B1/en

Links

Abstract

Peptides having high activity in the eliciting of a cytotoxic T lymphocyte response to the HIV-1 envelope glycoprotein gp160 are described. The activation of 12-15 residue peptides by proteolytic degradation to shorter peptides is shown as are general techniques for characterizing such activation processes.

Claims

49AMENDED CLAIMS[received by the International Bureau on 14 April 1994 (14.04.94); original claim 1 amended; remaining claims unchanged (1 page)]
1. A polypeptide comprising an amino acid sequence that is a portion of the HIV envelope glycoprotein gpl60 which elicits an immune response characterized by response of both HC class I-restricted and MHC class-II restricted elements of the mammalian immune system, said polypeptide eliciting said response in a solution at a concentration of peptide of less than 3 X 10"7 M.
2. An isolated polypeptide according to claim 1, wherein said portion of the HIV envelope glycoprotein gplβO is the region homologous to amino acids 318-327 of isolate IIIB.
3. An isolated polypeptide having an amino acid sequence selected from the group consisting of: RGPGRAFVTI, IGPGRAFYTT, IGPGRAFYAT, KGPGRVIYAT, IGPGRAFHTT, IGPGRTLYAR, LGPGRVWYTT, and IGPGRAFRTR.
4. An isolated polypeptide having the amino acid sequence RGPGRAFVTI .
PCT/US1993/001925 1992-03-06 1993-03-08 Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160 WO1993018055A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002131153A CA2131153C (en) 1992-03-06 1993-03-08 Peptides stimulating cytotoxic lymphocytes response to hiv-i gp 160
EP93907180A EP0630385A1 (en) 1992-03-06 1993-03-08 Potent peptide for stimulation of cytotoxic t lymphocytes specific for the hiv-1 envelope
AU37878/93A AU668927B2 (en) 1992-03-06 1993-03-08 Peptides stimulating cytotoxic lymphocytes response to HIV-I GP 160

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US847,311 1992-03-06
US07/847,311 US5976541A (en) 1988-01-26 1992-03-06 Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope

Publications (3)

Publication Number Publication Date
WO1993018055A2 WO1993018055A2 (en) 1993-09-16
WO1993018055A3 WO1993018055A3 (en) 1994-03-17
WO1993018055B1 true WO1993018055B1 (en) 1994-06-09

Family

ID=25300315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001925 WO1993018055A2 (en) 1992-03-06 1993-03-08 Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160

Country Status (5)

Country Link
US (1) US5976541A (en)
EP (1) EP0630385A1 (en)
AU (1) AU668927B2 (en)
CA (1) CA2131153C (en)
WO (1) WO1993018055A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
NL9400384A (en) * 1994-03-11 1995-10-02 Smit Victor Retrovirus vaccines, vaccination and immunotherapy against retroviral infections.
GB9426153D0 (en) * 1994-12-23 1995-02-22 Medical Res Council Improvements in or relating to vaccines
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
MXPA02007478A (en) 2000-02-04 2004-08-23 Univ Duke Human immunodeficiency virus vaccine.
EP1292330A1 (en) * 2000-03-31 2003-03-19 Vaccine Chip Technology APS Immunostimulating properties of a fragment of tgf- beta
WO2003037264A2 (en) * 2001-10-29 2003-05-08 Genzyme Corporation Therapeutic anti-hiv (vpr) compounds
US20030162720A1 (en) * 2001-10-29 2003-08-28 Nicolette Charles A. Therapeutic anti-HIV (IV9) compounds
US20090214583A1 (en) * 2004-04-30 2009-08-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Epitope-enhancement of a human cd4 hiv epitope
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201540B2 (en) * 1984-10-18 2001-10-31 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
ATE108022T1 (en) * 1985-10-24 1994-07-15 Southwest Found Biomed Res SYNTHETIC PEPTIDES AND THEIR USE IN DIAGNOSIS AND VACCINATION FOR AIDS AND ARC.
AU617088B2 (en) * 1986-06-12 1991-11-21 Biogen, Inc. Peptides involved in the pathogenesis of hiv infection
DE3787002T2 (en) * 1986-12-30 1993-11-25 Us Health Synthetic peptides that generate cellular immunity to the AIDS virus and its proteins.
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
WO1989007112A1 (en) * 1988-01-26 1989-08-10 The United States Of America, As Represented By Th A synthetic antigen evoking anti-hiv response
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
FR2650954B1 (en) * 1989-08-18 1992-02-28 Pasteur Institut COMPOSITION RESULTING FROM THE BINDING OF AN EPITOPE B OF THE ENVELOPE GLYCOPROTEIN OF A TYPE IV RETROVIRUS AND A T-EPITOPE HAVING A DISTINCT PROTEIN ENCODED BY THIS RETROVIRUS AND THEIR APPLICATION TO THE PRODUCTION OF PROTECTIVE ANTIBODIES AGAINST AIDS
US5254682A (en) * 1989-12-08 1993-10-19 Merck & Co., Inc. Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
JPH03271233A (en) * 1990-03-19 1991-12-03 Inst Pasteur Inducement of protective action against virus infection by synergism between peptides cor- responding to virus envelope glycoprotein and neutral epitope of its glycoprotein
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors

Similar Documents

Publication Publication Date Title
WO1993018055B1 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
EP1714974A3 (en) HIV-1-and HIV-2-peptides for inhibition of membranes fusion-associated events, including HIV transmission
CA2140663A1 (en) Compounds which inhibit hiv replication
NZ267803A (en) Synthetic peptides which inhibit hiv transmission and other viral diseases
EP1369427A3 (en) HIV-3 retrovirus strains and their use
WO1991009872A3 (en) Hiv-1 env fragment fusion protein
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
AU2010088A (en) Synthetic lipid vesicle carriers
CA2193210A1 (en) Method of inducing an immune response with a live venezuelan equine encephalitis virus expressing a heterologous immunogen
EP0328403A3 (en) Synthetic peptides related to the hiv-gp120-env-protein, and their use
CA2358915A1 (en) Modified hiv env polypeptides
WO1993018055A3 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
ES2010231A6 (en) Fusion proteins and particles.
EP0272858A3 (en) Recombinant hiv envelope proteins produced in insect cells
CA2084386A1 (en) Hiv antigen
HUT76102A (en) Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains
US5817315A (en) Recombinant vaccine
IL90391A0 (en) Peptides suppressing the function of the immune system,their preparation and pharmaceutical compositions containing them
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
WO2002077189A3 (en) Glycosylation-resistant and nonglycosylated cyanovirins
CA2086509A1 (en) Non-cleavable soluble hybrid gp160 variant
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
WO1998037089A8 (en) Matrix derived anti-hiv peptides and transdominant proteins
EP0551440A4 (en) Design of bioactive peptides based on immunoglobulin structure